Abstract
Background Observational studies have reported maternal short/long sleep duration to be associated with adverse pregnancy and perinatal outcomes. However, it remains unclear whether there are nonlinear causal effects. Our aim was to use multivariable regression (MVreg) and Mendelian randomization (MR) to examine nonlinear effects of sleep duration on stillbirth, miscarriage, gestational diabetes, hypertensive disorders of pregnancy, perinatal depression, preterm birth, low/high offspring birthweight (LBW/HBW).
Methods We used data from European women in UK Biobank (UKB, N=208,140), FinnGen (N=∼123,579), Avon Longitudinal Study of Parents and Children (N=6826), Born in Bradford (N=2940) and Norwegian Mother, Father and Child Cohort Study (MoBa, N=14,584). We used 78 previously identified genetic variants as instruments for sleep duration, and investigated its effectsusing two-sample MR and one-sample nonlinear MR (in UKB only). We compared MR findings with MVreg in MoBa (N=76,669), where maternal sleep duration was measured at 30 weeks.
Results In UKB, MR provided evidence of nonlinear effects of sleep duration on stillbirth, perinatal depression and LBW, but not for other outcomes. Shorter and longer duration increased stillbirth and LBW; shorter duration increased perinatal depression. For example, there was a lower risk of LBW with increasing duration (odds ratio 0.79 per one-hour/day (95% confidence interval (CI): 0.68, 0.93) in the shortest duration group and a higher risk (odds ratio 1.38 (95% CI: 1.06, 1.81) in the longest duration group, suggesting shorter and longer duration increased the risk. These were supported by the lack of evidence of a linear effect of sleep duration with any outcome using two-sample MR. In MVreg, risks of all outcomes (except for stillbirth showing opposite directions) were higher in the women reporting <5- and ≥10-hours/day sleep compared with the reference category of 8-9-hours/day, despite some wide CIs including the null. Nonlinear models fitted the data better than linear models for most outcomes(likelihood ratio P-value=0.02 to 3.2×10−52), except for stillbirth and gestational diabetes.
Conclusions Our results supported possible nonlinear sleep duration effects on perinatal depression and LBW. Statistical support for nonlinear models across outcomes suggests potential nonlinear effects on other outcomes that larger studies could detect.
Competing Interest Statement
K.T. has acted as a consultant for CHDI Foundation. D.A.L. has received support from Medtronic LTD and Roche Diagnostics for biomarker research that is not related to the study presented in this paper. The other authors report no conflicts.
Funding Statement
This work was supported by the University of Bristol and UK Medical Research Council (MM_UU_00011/1, MM_UU_00011/3 and MM_UU_00011/6), the US National Institute for Health (R01 DK10324), the European Research Council via Advanced Grant 669545, the British Heart Foundation (AA/18/7/34219 and CS/16/4/32482) and the National Institute of Health Research Bristol Biomedical Research Centre at University Hospitals Bristol NHS Foundation Trust and the University of Bristol. Q.Y. is funded by a China Scholarship Council PhD Scholarship (CSC201808060273). M.C.B. was funded by a UK Medical Research Council Skills Development Fellowship (MR/P014054/1) and a University of Bristol Vice Chancellor Fellowship during her contribution to this research. M.C.M. has received funding from the European Research Council under the European Union's Horizon 2020 research and innovation programme (grant agreement No 947684). M.C.M and S.E.H are partly funded by the Research Council of Norway (project No 320656) through its Centres of Excellence funding scheme (project No 262700). A.G.S. is supported by the study of Dynamic longitudinal exposome trajectories in cardiovascular and metabolic non-communicable diseases (H2020-SC1-2019-Single-Stage-RTD, project ID 874739). D.A.L. is a British Heart Foundation Chair (CH/F/20/90003) and a National Institute of Health Research Senior Investigator (NF-0616-10102). The UK Medical Research Council and Wellcome (Grant ref: 217065/Z/19/Z) and the University of Bristol provide core support for ALSPAC. This publication is the work of the authors and D.A.L. will serve as guarantor for the contents of this paper. A comprehensive list of grants funding is available on the ALSPAC website (http://www.bristol.ac.uk/alspac/external/documents/grant-acknowledgements.pdf); This research was specifically funded by Wellcome Trust (WT088806), and child's GWAS data was generated by Sample Logistics and Genotyping Facilities at Wellcome Sanger Institute and LabCorp (Laboratory Corporation of America) using support from 23andMe. BiB receives core funding from the Wellcome Trust (WT101597MA), a joint grant from the UK Medical and Economic and Social Science Research Councils (MR/N024397/1), British Heart Foundation (CS/16/4/32482), and the National Institute of Health Research under its Applied Research Collaboration for Yorkshire and Humber and Clinical Research Network research delivery support. Further support for genome-wide and multiple 'omics measurements in BiB is from the UK Medical Research Council (G0600705), National Institute of Health Research (NF-SI-0611-10196), US National Institute of Health (R01DK10324), and the European Research Council under the European Union's Seventh Framework Programme (FP7/2007-2013) / ERC grant agreement no 669545. The funders had no role in the design of the study; the collection, analysis, or interpretation of the data; the writing of the manuscript; or the decision to submit the manuscript for publication. The views expressed in this paper are those of the authors and not necessarily those of any funder.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethical approval for UKB was obtained from the North West Multi-centre Research Ethics Committee. Ethical approval for the study was obtained from the ALSPAC Ethics and Law Committee and the Local Research Ethics Committees. Ethical approval for BiB was obtained from the Bradford Research Ethics Committee. The establishment of MoBa and initial data collection was based on a license from the Norwegian Data Protection Agency and approval from The Regional Committees for Medical and Health Research Ethics. The MoBa cohort is now based on regulations related to the Norwegian Health Registry Act. The current study was approved by The Regional Committees for Medical and Health Research Ethics.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
We used both individual participant cohort data and publicly available summary statistics. We present summary statistics that we generated from those individual participant cohort data in Tables S3 & S7 in File S1. Full information on how to access UKB data can be found at its website (https://www.ukbiobank.ac.uk/researchers/). All ALSPAC data are available to scientists on request to the ALSPAC Executive via this website (http://www.bristol.ac.uk/alspac/researchers/), which also provides full details and distributions of the ALSPAC study variables. Similarly, data from BiB are available on request to the BiB Executive (https://borninbradford.nhs.uk/research/how-to-access-data/). Data from MoBa are available from the Norwegian Institute of Public Health after application to the MoBa Scientific Management Group (see its website https://www.fhi.no/en/op/data-access-from-health-registries-health-studies-and-biobanks/data-access/applying-for-access-to-data/ for details). Summary statistics from FinnGen are publicly available on its website (https://finngen.gitbook.io/documentation/data-download).
